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Objectives. The aims of this study were to determine whether 
hypertensive patients howed increased endogenous opioid tone 
and to find a possible correlation between beta-endorphin levels 
and 24-h ambulatory blood pressure. We also investigated 
whether circulating beta-endorphin levels were associated with 
pain perception at rest. 
Background. Experimental studies uggest an involvement of
the endogenous opioid system in cardiovascular control mecha- 
nisms. 
Methods. We determined baseline beta-endorphin plasma lev. 
els by radioimmunoassay in 81 consecutive subjects (48 hyperten- 
sive, 33 normotensive) after a 30-rain rest and before 24-h 
ambulatory blood pressure monitoring. In 72 of 81 subjects with a 
dental formula suitable for the pulpar test (graded increase of test 
current -0 to 0.03 mA applied to three healthy teeth), pain 
perception was also investigated. 
Results. Hypertensive patients howed higher beta-endorphin 
plasma levels than normotensive subjects (p < 0.002). Circulating 
endogenous opioid levels correlated with 24-h diastolic blood 
pressure (p < 0.01), whereas the relation with systolic pressure 
did not reach statistical significance. When 24-h blood pressure 
recordings were divided into daytime and nighttime values, and 
blood pressure loads (percent of measurements >140 mm Hg for 
systolic blood pressure and >90 mm Hg for diastolic pressure) 
were calculated, a significant correlation was found between 
beta-endorphin levels and diastolic pressures and load. Similarly, 
presampling diastolic blood pressure was significantly correlated 
with beta-endorphin levels. Of the 72 subjects tested, hypertensive 
patients howed a lower pain sensitivity than normotensive sub- 
jects. A positive correlation was found between pain threshold and 
circulating beta-endorphin levels (p < 0.05). 
Conclusions. Sustained arterial pressure is probably involved 
in the tonic activation of cardiovascular mechanisms linked to 
endogenous opioid tone. Circulating plasma endorphins may 
account, at least in part, for the pain perception pattern relating 
to blood pressure levels at rest. 
(J Am Coil Cardiol 1996;28:1243- 8) 
There is experimental evidence to suggest an important role 
for endogenous opioid peptides in cardiovascular control 
(1-14). These actions may result from an opioid modulation of 
central autonomic outflow or from the direct action of opiates 
(4-7). Interaction between beta-endorphin a d somatostatin, 
serotonin, atrial natriuretic peptide and cholinergic neurons 
has also been described (7-11). 
Endogenous opiates seem to act as neurotransmitters in 
central baroreflex pathways (1:1-13). Moreover, a baroreflex- 
induced release of beta-endorphins has been reported (11), 
demonstrating that endogenous opioids are released and may 
act in the periphery. Among the opioid peptides, beta- 
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endorphins appear to play a prominent role in the modulation 
of vascular functions. A beneficial effect of opiate receptor 
blocking during hemorragic hypotension was obtained by 
intracerebroventricular administration of antiserum against 
this peptide but not by antisera against other endogenous 
opioid peptides (14). 
Beta-endorphins have a primary role in the endogenous 
analgesia system, modulating pain perception (15-17). In 
contrast, several studies (2,18-25) have reported behavioral 
responses consistent with hypalgesia or reduced pain percep- 
tion in hypertension, using different methods to induce exper- 
imental pain. A previous tudy by our group (24) showed that 
the correlation between hypertension a d dental pain percep- 
tion was more striking when mean 24-h blood pressure values 
were considered with respect o office blood pressure. Ambu- 
latory blood pressure monitoring has been established as a 
useful method to provide a clear, accurate picture of hyper- 
tensive disease, particularly in investigational studies (26-30). 
Although clear evidence of the relation between pain percep- 
tion and blood pressure levels has been provided, controversial 
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data have been reported on circulating beta-endorphins in 
hypertensive humans (23,31-34). 
The aims of this study were 1) to evaluate whether baseline 
beta-endorphin plasma levels differed in normotensive and 
hypertensive subjects; 2) to determine whether blood pressure 
values obtained by office measurements and by noninvasive 
24-h blood pressure monitoring correlated with beta- 
endorphin plasma levels; and 3) to determine whether circu- 
lating beta-endorphin levels were related to dental pain per- 
ception. 
Methods  
Subjects. Forty-eight patients with essential hypertension 
(World Health Organization [WHO] class I to II) were studied 
consecutively together with a comparison group of 33 normo- 
tensive subjects. Patients with essential hypertension were 
drawn from our outpatient clinic population. A routine diag- 
nostic workup ruled out secondary forms of hypertension i
these subjects. The 33 normotensive subjects were recruited 
during an antihypertensive screening campaign (WHO crite- 
ria) among Italian post office employees. Criteria for inclusion 
in the study were 1) no medical therapy or pharmacologic 
washout (of antihypertensive tr atment), or both, for at least 3 
weeks before monitoring; 2) male gender; 3) age between 30 
and 50 years; and 4) no concomitant diseases (diabetes, 
neuropathies, cardiac diseases, obesity, lung disease, stroke or 
psychiatric disturbances). No subject was involved in compet- 
itive sports activities. 
Ambulatory blood pressure monitoring. All subjects un- 
derwent noninvasive ambulatory blood pressure monitoring by 
means of a device (Takeda TM2421, A&D Co., Tokyo, Japan) 
set to take a measurement every 15 rain for a period of 24 h 
(24). With this system, measurement errors are minimized 
because of the combined use of the Riva-Rocci-Korotkoff 
method and the oscillometric method for blood pressure 
measurements. 
The instrument was set to record measures first according 
to the auscultatory method, and in <15% of the measures of 
any single ambulatory blood pressure monitoring, the values 
were given according to the oscillometric technique. Six sub- 
jects in whom the quality of the 24-h ambulatory tracing was 
not sufficient (valid measures <80%) underwent repeat mon- 
itoring on the following day that was successful. 
A software system (W. Pabisch spa, Milan, Italy) was used 
for reading, editing and analysis of data. The following vari- 
ables (mean _+ SD) were included for analysis: 1) 24-h systolic 
and diastolic blood pressures; 2) diurnal (6 AM to 10 PM) (35) 
systolic and diastolic blood pressures; 3) nocturnal (10 PM to 
6 AM) systolic and diastolic blood pressures; 4) 24-h diurnal and 
nocturnal heart rates; and 5) percent of measurements 
throughout 24 h ->140 mm Hg for systolic blood pressure 
(systolic load) and ->90 mm Hg for diastolic blood pressure 
(diastolic load). Twenty-four hour systolic and diastolic blood 
pressure variation coefficients calculated with the formula 
SD/mean value × 100 (%) were also analyzed. 
Determination of beta-endorphin levels. Before ambula- 
tory monitoring, all subjects rested 30 rain in a comfortable, 
supine position, with a saline infusion (antecubital vein), 
between 9 and 11 AM. Afterward, 10-ml venous blood samples 
for determination of beta-endorphin plasma levels were ob- 
tained. During the rest period, blood pressure was measured 
every 3 rain by an automatic Hewlett-Packard 78352A re- 
corder. Before sampling, if blood pressure varied >5 mm Hg 
from the previous measurement, additional readings were 
taken until two were close (difference <5 mm Hg ["presam- 
piing blood pressure"]). 
The samples were immediately centrifuged at 4°C, and the 
plasma was aspirated and immediately frozen at -80°C until 
assay. Samples were purified by C18 Sep-Pack cartridges 
(Waters) and analyzed by a radioimmunoassay method (beta- 
endorphin-I125, RIA Kit, Peninsula) (36,37). Each sample was 
divided in two and analyzed separately by pharmacologists who 
had no knowledge of patient characteristics. Quality control 
was performed for each determination, and the coefficient of 
variation was <10% (37). 
All subjects were previously instructed to refrain from 
smoking and were studied after an overnight fast. In particular, 
they were asked not to consume coffee, tea, chocolates or 
cola-containing or alcoholic drinks during the previous 12 h. 
Pulpar test. Seventy-two of81 subjects (41 hypertensive, 31
normotensive) showed adental formula suitable for the pulpar 
test (i.e., absence of tooth fractures, abrasions, caries lesions, 
fillings and marked periodontal disease). They had dental pain 
perception evaluation immediately after blood sampling for 
determination of beta-endorphin levels by means of an elec- 
trical pulp stimulator commonly used in dentistry for clinical 
purposes (MEDI-tester, MEDIC-AL, Treviso, Italy). Three 
healthy teeth (two upper incisors and one inferior incisor, 
always in the same order) were tested in each subject, and 
mean values were used in subsequent analysis. 
As described previously (24), the pulpar tester allows 
delivery of automatic intermittent bursts of electrical stimuli 
with negative polarity at linearly increasing intensity from 0 to 
0.03 mA (maximal tension 6,500 mV). The burst frequency was 
set to 5 Hz. The stimulator was applied to the tooth through a 
metal cylinder (with an inner diameter of 0.9 mm) placed on 
the enamel surface. The circuit was closed by the operator's 
hand placed in contact with the subject's lips. As the test 
current increased from 0 to 0.03 mA, a number from 0 to 80 
(relative units [rU]) was displayed on a digital reader of the 
instrument, not visible to the subject under examination. All 
measurements were taken in blinded manner (i.e., without he 
dentist's knowing the subject's blood pressure). 
Subjects were previously instructed to raise their right hand 
at the occurrence of pain or when they wanted to stop the 
delivery of test current. Pain threshold (expressed in rU) was 
defined in all subjects as the minimal intensity of test current 
that elicited any pulp sensation (24,38). At this point, the 
stimulation was interrupted. Pain tolerance (rU) was obtained 
immediately afterward by reapplying the test current and 
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Table 1. Demographic Data and Blood Pressure and Heart 
Rate Values 
Normotensive Hypertensive 
Subjects Patients 
(n = 33) (n - 48) p Value 
Age (yr) 42 _+ 5 43 2 6 0.43 
Body mass index (kb'm 2} 24.5 _+ 0.5 24.2 + 0.9 0.09 
Current smoker 6 (18%) 8 (17%) 0.86 
24-h SBP (ram Hg) 123 + 8 150 _+ 15 < 0.001 
24-h DBP (mm Hg) 77 + 8 95 _+ 8 < 0.001 
24-h HR (beats/rain) 72 _+ 8 77 +_ 12 < 0.05 
Daytime SBP (ram Hg) 129 = 9 156 + 16 < 0.001 
Daytime DBP (mm Hg) 81 = 9 98 _+ 8 < 0.001 
Nighttime SBP (mm Hg) 110 _+ 10 136 _+ 17 < 0.001 
Nighttime DBP (mm Hg) 68 _+ 9 88 _+ 11 < 0.001 
SBP load (%) 19 _+ 14 59 _+ 27 < 0.001 
DBP load (%) 20 _+ 15 63 + 24 < 0.001 
Presampling SBP (ram Hg) 136 _+ 12 155 _+ 16 < 0.001 
Presampling DBP (mm Hg) 84 _+ 11 100 _+ 10 < 0.001 
Presampling HR (beats/min) 65 _+ 12 69 _+ 12 0.14 
Data presented are mean value _+ SD or number (%) of patients. DBP - 
diastolic blood pressure; HR - heart rate; SBP = systolic blood pressure. 
continuing stimulation until subjects asked for the test to be 
stopped (24). 
All subjects gave written informed consent to the study and 
before any procedure. The study protocol was approved by the 
ethical committee of our department (Varese). 
Statistical analysis. Results are reported as mean value + 
SD for quantitative variables and as absolute and relative 
frequencies for qualitative variables. A Cochran's variance 
homogeneity test was performed. Because the data concerning 
pain perception were not homogeneous, they were trans- 
formed to natural ogarithms (ln). After transformation, no
other significant differences among variables were detected. 
Differences between mean values were evaluated by the Stu- 
dent test, and differences in beta-endorphin levels in normo- 
tensive and hypertensive subjects were compared by the Mann- 
Whitney U test. A chi-square test was performed to compare 
qualitative variables (smoking habits). Relations among vari- 
ables were investigated by linear regression analysis. A Spear- 
man rank correlation was performed to test correlations 
between beta-endorphin levels and blood pressure and pain 
perception values. All analyses were performed using an 
SPSS-PC+ package on an IBM personal computer. A p value 
<0.05 was considered significant. 
Resu l ts  
Blood pressure and demographic data. The clinical char- 
acteristics of the 81 subjects are shown in Table 1. There were 
no differences between the groups other than those in blood 
pressure l vels due to the selection criteria. The 24-h heart rate 
was also slightly higher in hypertensive subjects. 
Beta-endorphin levels. Baseline beta-endorphin plasma 
levels were significantly higher in hypertensive patients than in 
normotensive subjects (p < 0.002) (Table 2). Beta-endorphin 
Table 2. Descriptive Statistics of Beta-Endorphin Levels in 
Normotensive and Hypertensive Subjects 
Beta-Endorphin Levels (pg/ml) 
Normotensive Hypertensive 
Subjects Patients 
Average 1.91 3.74 
SD 1.86 2.31 
Median 1.33 4.7 
Minimal value 0.1 0.1 
Maximal value 6.5 7.21 
levels were significantly correlated with diastolic 24-h blood 
pressure, whereas the relation with systolic blood pressure did 
not reach statistical significance. When 24-h blood pressure 
recordings were divided into daytime and nighttime values, 
and blood pressure loads were calculated, a significant corre- 
lation was found between beta-endorphin levels and diastolic 
blood pressures and load. Similarly, presampling diastolic 
blood pressure was significantly correlated with beta- 
endorphin levels, whereas presampling systolic blood pressure 
was not. The coefficient of variation of diastolic blood pressure 
was also related to endogenous opioids. Table 3 shows corre- 
lation coefficients and their significance. 
Pulpar test. In 72 subjects undergoing the pulpar test, the 
results showed a significant difference in pain threshold and 
tolerance, which were higher in the hypertensive group (pain 
threshold: 3.06 _+ 0.24 In rU vs. 3.24 _+ 0.32 In rU, p < 0.02; 
pain tolerance: 3.5 _ 0.41 In rU vs. 3.68 +_ 0.4 In rU, p < 0.05 
[normotensive group vs. hypertensive group, respectively]) 
(Fig. 1). Pain threshold was significantly correlated with both 
24-h systolic and diastolic blood pressure (r = 0.37, p < 0.001; 
r = 0.28, p < 0.02, respectively), whereas pain tolerance was 
not. Circulating beta-endorphin levels were slightly, but signif- 
icantly, correlated with pain threshold, whereas pain tolerance 
was not (r = 0.25, p < 0.05, r = 0.15 p = 0.2, respectively). 
Table 3. Spearman Rank Correlation Coefficients Between 
Beta-Endorphin Plasma Levels and Blood Pressure Values 
r Value p Value 
24-h SBP 0.20 0.08 
24-h DBP 0.30 < 0.01 
Daytime SBP 0.17 0.14 
Daytime DBP (I.27 < 0.02 
Nighttime SBP 0.19 0.09 
Nighttime DBP 0.31 < 0.01 
SBP load 0.15 0.18 
DBP load 0.27 < 0.02 
CoV 24-h SBP -0.16 0.16 
CoV 24-h DBP 0.32 < 0.01 
Presampling SBP (I.18 0.11 
Presampling DBP (/.22 < 0.05 
CoV = coefficient of variation; other abbreviations as in Table 1. 
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Figure 1. Dental pain threshold and tolerance are expressed in natural 
logarithm of relative units (In rU). In 72 of 81 subjects tested with a 
dental formula suitable for the pulpar test, the results howed a 
significant difference in dental pain threshold and tolerance, which 
were higher in hypertensive (open bars) than normotensive subjects 
(solid bars) (p < 0.02 and p < 0.05, respectively). 
Discuss ion 
The endogenous opiate system is involved in cardiovascular 
control mechanisms of arterial pressure both in normal and 
pathologic onditions (39-43). The presence of hypertension 
is associated with different anatomic distributions of opiate 
receptor-binding in the brain and different beta-endorphin 
levels in discrete cerebral regions (41,44-46). In addition, a 
modified response of the opiate system to stimuli from sym- 
pathoadrenal control is consistent with functional changes 
(41,47). Moreover, changes in peripheral opioid function 
mechanisms have been reported in hypertensive animals 
(48,49). 
Beta-endorphin plasma levels in hypertensive patients. 
Previous reports on circulating beta-cndorphin levels in hyper- 
tensive patients were controversial. Some studies reported that 
circulating beta-cndorphin levels were higher in hypertensive 
patients than in control subjects, whereas others did not 
(23,31-33). Moreover, the premorning peak of beta-endorphin 
levels was reported to be lower in hypertensive patients (32). 
Although beta-endorphin plasma levels at morning peaks were 
similar, possible involvement of low circulating opioid levels as 
a cause of high blood pressure values was proposed (32). Some 
studies reported (31) a significant difference in beta-endorphin 
plasma levels between hypertensive patients and normotensive 
subjects only after the use of alphas-stimulating agents. The 
present study showed higher baseline beta-endorphin levels in 
hypertensive patients than in normotensive subjects. The small 
number of patients evaluated in most of the previous tudies 
may have influenced the results. High levels of circulating 
hypotensive factors, such as beta-endorphins, may be a re- 
sponse to high blood pressure, possibly mediated at the 
baroreceptor level. However, a genetic trait linking the opiate 
system and cardiovascular functions cannot be ruled out 
(50,51). Indeed, a great overlap between ormotensive and 
hypertensive subjects in beta-endorphin plasma levels was 
observed in the present study, possibly indicating a major role 
for personality, and emotional factors on circulating opioid 
levels. 
We found a significant correlation between beta-endorphin 
levels and 24-h diastolic ambulatory pressures, whereas pre- 
sampling blood pressure values were less associated with 
endogenous opiates. Beta-endorphin plasma levels were cor- 
related with 24-h, daytime and nighttime diastolic arterial 
pressures and diastolic load, whereas the relation with systolic 
pressures did not reach statistical significance. One report (52) 
on beta-endorphin levels in arnniotic fluid in pregnancies 
complicated with hypertension showed a significant linear 
correlation with maternal diastolic and mean office blood 
pressure. However, it was suggested that this finding was 
related to activation of the fetal endogenous opioid system 
more than to a maternal opioid response to elevated blood 
pressure. Other investigators have reported (23) a correlation 
between beta-endorphins levels and mean blood pressure 
values in hypertensive patients and normotensive subjects. 
We studied a comparatively arge patient cohort, but the 
correlation between systolic blood pressure and circulating 
endorphin levels was not significant; it is possible that a larger 
patient sample may be necessary. In the present study, the 
positive correlation between beta-endorphin levels and sus- 
tained blood pressure values (mean values and load) seems 
to indicate that the linkage between arterial pressure and 
endogenous opioids reflects a long-lasting pattern. However, 
neural mechanisms probably play a major role in determining 
opioid tone, and blood pressure is only one factor that may 
influence circulating endorphins. With regard to variability 
expressed by the blood pressure coefficient of variation, the 
negative correlation with beta-endorphin levels stresses the 
relevance of persistently high diastolic blood pressure values 
to circulating opioid levels. Because a closer correlation was 
found between beta-endorphin levels and nocturnal arterial 
pressure values, it may also be that tonic interaction between 
blood pressure and opiate tone becomes more apparent at 
night, when other pressure regulatory systems are less acti- 
vated. 
Hypertension and pain perception. Several reports (18- 
25) in animals and a few in humans have described a reduced 
perception of experimental pain associated with high blood 
pressure. Pain perception is affected by numerous ubstances 
and various pathways. Serotonin, catecholamines, substance P,
met-enkephalins and beta-endorphins may affect he transmis- 
sion of painful sensations (15,16). Moreover, relations between 
substances acting both on analgesia nd blood pressure control 
have been described, and among these, the interaction be- 
tween catecholamines and beta-endorphins seems to be par- 
ticularly relevant (53-55). The activation by opiates of the 
descending system of pain modulation and local actions of 
opiates at the spinal level produce analgesia (15-17). Because 
naloxone was found to be partially capable of reverse 
hypertension-related hypalgesia, arole for endogenous opiates 
as a linkage between high blood pressure and reduced pain 
sensitivity, has been suggested (2,18-20). 
Despite considerable overlap in pain perception values, the 
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present study confirms a reduced dental pain sensitiviW in 
hypertensive patients and a positive correlation between 24-h 
blood pressure and pain thresholds (24). A slight but signifi- 
cant correlation was found between pain threshold and beta- 
endorphin levels. A previous study (23) in hypertensive pa- 
tients failed to correlate thermal pain sensitivity with 
endogenous opioid levels, and a recent report (56) in patients 
with coronary artery disease showed a significant correlation 
between pain threshold and beta-endorphin levels only after a 
stress test, with no association of baseline values. The correla- 
tion between endorphin levels and pain perception may be- 
come more apparent after stimulus. Although a recent study 
on pain sensitivity in normotensive subjects (57) suggested that 
the relation between basal blood pressure and pain perception 
may be mediated, at least in part, by nonopioid mechanisms, 
our data seem to indicate a role for circulating beta- 
endorphins in pain perception, even at baseline conditions. 
Conclusions. The present study demonstrated higher cir- 
culating beta-endorphin levels in hypertensive patients than in 
normotensive subjects. Baseline endogenous opioid levels are 
related to 24-h blood pressure values, indicating that sustained 
diastolic arterial pressure is involved in the tonic activation of 
the endogenous opioid system. Hypertension-related hypalge- 
sia was confirmed. Because circulating plasma endorphin levels 
were correlated with pain threshold, plasma endorphins may 
link, at least in part, the pain perception pattern to blood 
pressure levels. 
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